Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations

A pooled analysis of 536 psilocybin sessions across 14 studies reveals that the drug causes only modest, transient blood pressure elevations comparable to moderate exercise, suggesting that current cardiovascular exclusion criteria are overly conservative and should be broadened to include individuals with baseline blood pressure under 160/100 mmHg.

The Gist

Imagine the human body as a car engine. For years, doctors have been very cautious about letting anyone with a slightly "warm" engine (high blood pressure) drive a new, powerful vehicle called psilocybin. The rule was strict: if your engine temperature was above a certain level (140/90 mmHg), you weren't allowed to get in the car, even if you were otherwise healthy. This rule was set up based on a "better safe than sorry" guess, not on actual data from driving the car.

This new study is like a massive test drive logbook. Researchers at Johns Hopkins gathered data from 536 test drives (psilocybin sessions) involving 368 different drivers over many years. They wanted to see exactly what happens to the engine when you hit the gas with this specific vehicle.

Here is what they found, translated into everyday terms:

1. The Engine Revs, But Not Out of Control

When the drivers took the psilocybin, their blood pressure (engine temperature) did go up. Think of it like stepping on the gas pedal.

• The Peak: The engine revved up the most about 90 minutes after starting.
• The Magnitude: The average increase was about 22 points. The authors compare this to the effort of moderate exercise (like a brisk walk or climbing a flight of stairs) or even having sex. It's a temporary spike, not a runaway train.
• The Cool Down: Just like after a workout, the engine cooled down on its own. By 5 hours (300 minutes), the blood pressure was back to almost normal.

2. The "Overheating" Myth

The biggest surprise was about the drivers who started with a warmer engine (higher baseline blood pressure).

• The Old Fear: Doctors worried that if you started with high blood pressure, the psilocybin would make it skyrocket dangerously.
• The Reality: It was the opposite. Drivers who started with higher blood pressure actually saw smaller spikes. It's as if their engine had a "ceiling" or a governor that prevented it from revving any higher. The people with the "coolest" engines actually saw the biggest relative jumps.

3. How Often Did Things Get Dangerous?

The researchers looked for "red lights" (extremely high blood pressure).

• High Spikes: Only 6% of the sessions saw the systolic pressure (the top number) go above 170. Even then, it only lasted about 8 to 10 minutes on average.
• Extreme Spikes: Only 2 sessions out of 536 hit the "severe" danger zone (over 180/120).
• Medicine Needed: In the entire history of these 536 drives, doctors only had to give a blood-pressure-lowering pill once (0.2% of the time). No one had a heart attack, stroke, or other serious trouble because of the blood pressure.

4. The Heart Rate

The heart rate (the RPMs) also went up, but it was even milder than the blood pressure. It peaked later, around the 3-hour mark, and stayed manageable. The study found no reason to ban anyone just because their heart beats a little fast before they start.

The New Recommendation

Based on this data, the authors are suggesting we update the "driver's license" rules for this therapy:

• The Old Rule: You must have blood pressure under 140/90 to participate.
• The New Proposal: You can participate if your blood pressure is under 160/100.
  • If you are already taking medication for blood pressure and it's stable, you can join.
  • Doctors can use their judgment to let people with slightly higher readings (up to 170/105) on the day of the session, provided they don't have serious heart disease.
  • The "No-Go" Zone: People with established heart disease (like past heart attacks or heart failure) should still be excluded, just as they would be for many other medical treatments.

Why This Matters

The authors point out that the old, strict rules were accidentally locking out many people who could benefit from this therapy. People with depression, addiction, or PTSD often also have high blood pressure. By keeping the bar at 140/90, the study suggests we were unfairly excluding a large group of people who, according to this data, would have been perfectly safe to treat.

In short: Psilocybin acts like a temporary, moderate workout for your heart and blood vessels. It doesn't break the engine, even if the engine was already running a bit warm. The data suggests we can safely widen the door to let more people in, as long as we keep monitoring them for those first 6 hours.

Technical Summary

1. Problem Statement

Psilocybin is increasingly utilized as a therapeutic agent for psychiatric conditions (e.g., depression, PTSD, substance use disorders). However, clinical trials and emerging therapeutic practices currently employ overly conservative cardiovascular exclusion criteria, typically barring individuals with resting blood pressure (BP) $\ge$ 140/90 mmHg. These criteria were established without robust empirical data specific to psilocybin administration. Consequently, a significant population of patients—particularly those with hypertension who often suffer from the very conditions psilocybin treats—are unnecessarily excluded, raising concerns regarding equity, access, and the generalizability of trial results. There is a critical need to characterize the acute hemodynamic effects of therapeutic psilocybin doses to establish evidence-based safety protocols.

2. Methodology

• Study Design: A pooled retrospective analysis of cardiovascular safety data from 14 clinical studies conducted at Johns Hopkins University School of Medicine between 1999 and the present.
• Dataset:
  • Participants: 368 adults (mean age 44.8 years; 55.6% female; 89.1% White).
  • Sessions: 536 psilocybin administration sessions.
  • Dosing: Oral psilocybin doses ranging from 20 mg to 47.4 mg (therapeutic range).
  • Indications: Included major depressive disorder, cancer-related distress, PTSD, OCD, anorexia nervosa, Alzheimer's-related distress, Lyme disease, and healthy volunteer studies.
• Data Collection:
  • BP (systolic/diastolic) and heart rate (HR) were measured at baseline and hourly (or more frequently if elevated) up to 360 minutes post-administration.
  • Outcomes: Peak BP/HR, change from baseline, proportion of sessions exceeding specific thresholds (e.g., SBP >170, >180, >200 mmHg), and duration of excursions.
• Statistical Analysis:
  • Used locally estimated scatterplot smoothing (LOESS) for time-course visualization.
  • Median and Interquartile Range (IQR) reported for peak values due to right-skewed distributions.
  • Linear regression and mixed-effects models analyzed relationships between baseline parameters (BP, age, weight) and peak hemodynamic responses.

3. Key Results

• Hemodynamic Profile:
  • Psilocybin induces modest, transient elevations in BP and HR.
  • Peak Timing: Systolic BP (SBP) peaked at ~90 minutes post-dose; Heart Rate peaked later at ~180 minutes.
  • Recovery: BP returned to near-baseline levels by 300 minutes (5 hours).
• Magnitude of Change:
  • Median Peak SBP: 145 mmHg (IQR 134–156), representing a median increase of 22 mmHg from baseline.
  • Median Peak HR: 85 bpm (median increase of 14 bpm).
  • Comparison: The magnitude of BP elevation is comparable to moderate exercise or sexual activity.
• Threshold Excursions (Safety Events):
  • SBP >170 mmHg: Occurred in 6.0% of sessions (median duration 8.5 min).
  • SBP >180 mmHg: Occurred in 3.2% of sessions (median duration 10 min).
  • Severe Hypertension (SBP >180/DBP >120): Occurred in only 2 sessions (0.4%).
  • Intervention: Antihypertensive medication was administered in only 1 session (0.2%). No adverse cardiovascular sequelae were reported.
• Baseline Correlations (Ceiling Effect):
  • Contrary to the hypothesis that high baseline BP leads to exaggerated responses, a ceiling effect was observed.
  • Higher baseline BP was associated with smaller peak increases (e.g., for every 10 mmHg higher baseline SBP, the peak increase was 2.0 mmHg smaller).
  • Participants with baseline BP $\ge$ 140/90 mmHg showed smaller relative increases than normotensive participants.
• Demographic Factors:
  • Age: Older age was independently associated with larger peak BP increases (~4 mmHg greater SBP rise per decade).
  • Weight: Higher body weight was associated with modestly larger SBP increases.
  • Sex: No significant association with BP response.

4. Key Contributions

• Evidence-Based Eligibility Revision: The study provides the first robust empirical basis to challenge the standard exclusion criterion of BP $\ge$ 140/90 mmHg.
• Proposed Safety Guidelines:
  • Eligibility: Recommend broadening eligibility to resting BP <160/100 mmHg.
  • Dosing Day Flexibility: Allow dosing with baseline SBP 160–170 mmHg or DBP 100–105 mmHg at physician discretion; recommend against dosing if SBP >170 or DBP >105 mmHg.
  • Medication: Permit individuals on stable antihypertensive regimens (if no history of hypertensive emergency or major cardiovascular disease).
  • Heart Rate: Recommend against excluding participants based solely on heart rate elevations.
• Monitoring Protocol: Suggests a streamlined monitoring schedule (Baseline, 1.5h, 3h, 6h) rather than continuous hourly monitoring, reserving increased frequency for sustained elevations ($\ge$180/110 mmHg).

5. Significance

• Clinical Impact: These findings suggest that current exclusion criteria are not supported by safety data and unnecessarily restrict access to psilocybin therapy for populations with high comorbidity rates (e.g., hypertension, depression, substance use disorders).
• Equity: Relaxing criteria addresses health equity issues, as hypertension disproportionately affects Black adults and lower socioeconomic groups, who are often excluded from trials.
• Risk Stratification: The data indicates that psilocybin is safe for individuals with mild-to-moderate hypertension, provided they do not have established cardiovascular disease (e.g., prior MI, heart failure).
• Future Research: The authors call for prospective trials enrolling participants with baseline BP between 140/90 and 160/100 mmHg to further validate these safety recommendations.

Conclusion: Psilocybin produces predictable, transient hemodynamic changes comparable to moderate physical stress. The study concludes that the current exclusion threshold of 140/90 mmHg is unjustified and recommends raising the limit to 160/100 mmHg to expand therapeutic access while maintaining safety through targeted monitoring and exclusion of those with established cardiovascular disease.